Gene therapy for Bietti crystalline corneoretinal dystrophy: A phase 1/2 clinical trial
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.01.005 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2026. Verfasst von Liping Yang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China. Electronic address: alexlipingyang@bjmu.edu.cn. Hauptthemen laut MEDLINE: Genetic Therapy, Corneal Dystrophies, Hereditary, Retinal Diseases, Genetic Vectors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, Tianjin Municipal Natural Science Foundation, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Bietti crystalline corneoretinal dystrophy (BCD) is an inherited retinal degeneration caused by bi-allelic variants in the CYP4V2 gene. Here, we report a phase 1/2, dose-escalation clinical study to assess the safety and efficacy of ZVS101e, an adeno-associated viral (AAV)-mediated gene-augmentation therapy (rAAV2/8-hCYP4V2), in 11 BCD patients with up to 365 days of follow-up (NCT05832684). ZVS101e showed a favorable safety profile, with no dose-limiting toxicities or drug-related serious adverse events. Inflammatory response was observed, primarily in the medium- and high-dose groups, which were effectively managed with corticosteroids. Efficacy was optimal in the low-dose group, with mean best-corrected visual acuity improvement of 14.0 letters and 50% of participants achieving clinically meaningful gains (≥15 letters). Functional assessments, including a multi-luminance mobility test and Visual Function Questionnaire-25, along with retinal structure, demonstrated consistent improvements. These results highlight ZVS101e's therapeutic potential for BCD, supporting further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China. Electronic address: alexlipingyang@bjmu.edu.cn.
- Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 3…
- Clinical Development Department, Chigenovo Co., Ltd., Beijing 102200, China.
- Department of Ophthalmology, West China Hospital, Chengdu, Sichuan 610041, China.
- Research & Development Department, Chigenovo Co., Ltd., Beijing 102200, China.
- Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.
Förderung
- National Key Research and Development Program of China
- Tianjin Municipal Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Tianjin Municipal Education Commission
- Beijing Science and Technology Planning Project
Zitieren
APA
Yang, L., Xing, D., Zhang, J., Liu, B., Jiang, X., Chen, S., Li, W., Qu, B., Qiao, J., Feng, X., Jia, H., Hu, X., Yu, S., Jia, R., Wang, L., Mahajan, V. B., Dou, H., Lu, F., & Li, X. (2026). Gene therapy for Bietti crystalline corneoretinal dystrophy: A phase 1/2 clinical trial. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.01.005
Vancouver
Yang L, Xing D, Zhang J, Liu B, Jiang X, Chen S, et al. Gene therapy for Bietti crystalline corneoretinal dystrophy: A phase 1/2 clinical trial. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.01.005
BibTeX
@article{Yang2026,
author = {Yang, Liping and Xing, Dongjun and Zhang, Jinlu and Liu, Boshi and Jiang, Xiaoshuang and Chen, Shaohong and Li, Wang and Qu, Baoyuan and Qiao, Jing and Feng, Xuefeng and Jia, Haicun and Hu, Xianjun and Yu, Shicheng and Jia, Ruixuan and Wang, Likun and Mahajan, Vinit B and Dou, Hongliang and Lu, Fang and Li, Xiaorong},
title = {Gene therapy for Bietti crystalline corneoretinal dystrophy: A phase 1/2 clinical trial},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.01.005}
}
EUVIMED